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Background: The Snaith-Hamilton-Pleasure-Scale (SHAPS) is a self-reported scale evaluating anhedonia for
neuropsychiatric disorders. It has demonstrated with impressive psychometric properties and advantages in its
applicability over other similar instruments. However, very few studies have been conducted to examine the clinical
utility of the SHAPS in the context of Chinese settings. The current study aimed to examine the clinical utility of the
translated version of the SHAPS in the Chinese clinical settings.
Methods: A Chinese version of SHAPS was administered to 336 college students to examine the internal
consistency and test-retest reliability at a 4-week interval. Moreover, the translated SHAPS was also administered to
141 patients with major depression, 72 patients with schizophrenia, and 72 healthy controls to examine its
clinical discrimination.
Results: The internal consistency of the SHAPS for the non-clinical sample and test-retest reliability at a 4- week
interval were 0.85 and 0.64, respectively. Moreover, the SHAPS also showed an excellent internal consistency (alpha
was 0.93) and a one-factor solution with the first factor accounted for 51.53% of the variance in the clinical
psychiatric samples. ANOVA of the SHAPS total score indicated that the patients with depression scored
significantly more anhedonia than the patients with schizophrenia and healthy controls (p<0.001), and the patients
with schizophrenia scored significantly more anhedonia than the healthy controls (P<0.02).
Conclusions: These findings suggest that the Chinese version of the SHAPS is a useful and promising instrument in
assessing anhedonia for clinical patients and non-clinical individuals in the Chinese settings.
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Anhedonia refers to the inability to experience pleasure or
a related reduction of ability to react to pleasurable stim-
uli, which has been considered to be one of the key fea-
tures for major depression and schizophrenia [1].
Individuals with anhedonia generally display reduced re-
ward sensitivity [2] or decreased physical response (e.g.,
heart rate and facial expressions) to emotion-eliciting pic-
tures or words [3]. Although laboratory measures have the
advantage of providing an objective, quantifiable measure
of hedonic capacity, the highly constraint laboratory-
based environment has its limitations to everyday life situ-
ation which is more complex and full of distracters.* Correspondence: rckchan@psych.ac.cn
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reproduction in any medium, provided the orTherefore, the use of self-reported checklist is still very
useful for clinical assessment. The most commonly used
scales in depression research are the Snaith-Hamilton
Pleasure Scale (SHAPS) [4], the Fawcett-Clark Pleasure
Capacity Scale (FCPS) [5], and the Revised Chapman Phys-
ical Anhedonia Scale (CPAS) [6]. Leventhal et al. (2006)
have examined the psychometric properties of these three
self-reported scales. Confirmatory factor analysis demon-
strated that both the SHAPS and FCPS, but not the CPAS,
defined a hedonic capacity construct which was different
from depression and anxiety, and hedonic capacity was
largely defined by the SHAPS with the highest factor load-
ing on the hedonic capacity variable among the three
scales [7]. In addition, the SHAPS also shows more merits
over the other similar scales for its brevity and less subject
to cultural, sex and age biases [4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.














TEPS total score(20–120) 84.89±11.95
Data are presented as n or mean ± SD.
Notes: SHAPS is the Snaith–Hamilton Pleasure Scale, SWLS is the Satisfaction
with Life Scale, PANAS is the Positive and Negative Affect Scales, PANAS-PA is
the PANAS Positive affect subscale, PANAS-NA is the PANAS Negative affect
subscale, BDI is the Beck Depression Inventory, BAI is the Beck Anxiety
Inventory, TEPS is the Temporal Experience of Pleasure Scale, TEPS-ANT is the
TEPS anticipatory pleasure subscale, TEPS-CON is the TEPS consummatory
pleasure subscale.
Table 2 Characteristics of the patients with depression,










Gender (M/F) 29/43 36/36 63/78
Age (years) 30.88±10.45 33.12 ±11.09 30.84±10.41
Education (years) 12.52±2.29 12.04±3.17 11.88±3.13
BDI (0–63) 2.91±2.90 9,90±10.18 20.51±12.81
SHAPS (14–56) 21.50±5.17 24.25±7.09 28.15±7.74
TEPS-ANT (11–66) 45.29±7.34 40.34±9.20 40.77±7.60
TEPS-CON (9–54) 39.18±7.59 33.11±7.94 32.26±7.54
TEPS total score 84.47±12.46 73.45±15.92 73.04±13.97
Data are presented as n or mean ± SD.
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domains of hedonic experience, namely interest/
pastimes, social interaction, sensory experience, and
food/drink. It has been widely used and translated to dif-
ferent versions including French [8], German [9], Dutch
[10], American [11], Japanese [12] and Italian [13]. Im-
pressive psychometric properties and clinical utility have
been demonstrated in these versions [8-10,13]. However,
to our knowledge, most of the previous studies have
been limited to western samples. Very few of them have
been done in the non-western samples.
The purpose of the present study was to validate
the translated version of the SHAPS in the Chinese set-
tings. In particular, we aimed to examine the internal
consistency, convergent and divergent validity, and a
test-retest reliability of the SHAPS in a non-clinical sam-
ple. Moreover, we further examined its clinical utility




For validating the SHAPS in the non-clinical sample,
336 college students (57.1% females) were recruited from
two universities located in Guangzhou and Beijing in
China. The mean age of the sample was 19.43 years
(SD=1.02; range 18–22 years). Fifty-six participants
(22 males and 34 females) were randomly invited to
complete the SHAPS 4 weeks later. The mean age of
these re-test participants was 19.7 years (SD=0.87).
Moreover, 141 out-patients with depression and 72 in-
patients with schizophrenia, and 72 healthy controls
were recruited to examine the clinical validation and dis-
crimination of this scale. All patients were recruited
from Guangzhou Psychiatric Hospital. Clinical diagnoses
were determined based on the Structured Clinical Inter-
view for DSM-IV [1] by the experienced psychiatrists
(LZW,YHZ,MHL). Patients with any other concurrent
Axis I disorders were excluded in this study. The healthy
controls were recruited from the local community and
were screened by the experienced psychiatrists to ascer-
tain the healthy controls did not have any neuropsychi-
atric symptoms. There was no significant difference
among these three groups on gender, age and the level
of education. Tables 1 and 2 summarize the demo-
graphic information for the current samples.
Measure of anhedonia severity
The Snaith-Hamilton Pleasure Scale (SHAPS) [4] was
used to assess the anhedonia for the current study. It is
a 14-item checklist to assess individual’s pleasure experi-
ence in the “last few days”. It was rated on a 4-point
Likert scale from definitely agree to definitely disagree
instead of the original dichotomous scoring (agree anddisagree score 0 and 1) proposed by Snaith et al. [4].
The total score ranges from 14 to 56 for the Chinese
version of the SHAPS. This scoring method has also
been adopted by the validation studies of the Japanese
[12] and Dutch [10] versions of the SHAPS. The advan-
tage of this method is that it allows us to yield a more
dispersion of the data to calculate the internal
consistency, construct validity, and convergent correla-
tions with other scales.
Permission was obtained from the original author of
the scale for translation and research purposes. The
translation underwent a 2-stage translation process. The
first author of this manuscript and an independent pro-
fessional translator translated the SHAPS into Chinese.
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English by two postdoctoral students who did not get
involved in the original validation process. The final
translation was examined by an expert panel consisting
of clinicians and researchers to ascertain the items are
culturally relevant and can be correctly understood by
the Chinese participants.
Measures of convergent validity
The Temporal Experience of Pleasure Scale (TEPS) [14]
was used as a concurrent measure of anhedonia to
evaluate different components of the long-term experi-
ence of pleasure, namely the anticipatory and consum-
matory among the participants. The original English
version of TEPS has good internal consistency and test-
retest reliability [14]. The current study used a 20-item
Chinese version that was modified from the original
English version (18 items) to consider cultural differ-
ences. The Chinese version of TEPS has been proved to
possess adequate reliability in previous studies [15-17].
The Cronbach’s alphas for TEPS-ANT (anticipatory
pleasure) and TEPS-CON (consummatory pleasure) in
the current sample were 0.66 and 0.73, respectively.
The Beck Depression Inventory (BDI) [18], Positive
and Negative Affect Scales (PANAS) [19] and Satisfac-
tion with Life Scale (SWLS) [20] were chosen because
the absence of hedonic tone may influence individuals’
emotional state and feeling about life. The Beck Depres-
sion Inventory (BDI) is a 21-item scale that evaluates the
severity of depression. The Chinese version of BDI has
excellent psychometric properties [21] and the alpha in
the current sample for BDI was 0.83.
The Positive and Negative Affect Scales (PANAS) [19]
include 20 items that assess positive and negative affect.
The psychometric properties of the Chinese version of
the PANAS scales are good [22]. In the present sample,
the Cronbach’s alphas for positive affect and negative
affect were 0.84 and 0.85, respectively.
The Satisfaction with Life Scale (SWLS) [20] is a 5-
item scale to assess global life satisfaction. The Chinese
scale has good psychometric properties[23] and the
alpha in the current sample was 0.77.
Measure of divergent validity
The Beck Anxiety Inventory (BAI) [24] was used to
evaluate the divergent validity of the SHAPS. The Beck
Anxiety Inventory (BAI) is a 21-item scale that assesses
anxiety symptoms. The Chinese version of the scale has
been validated in Chinese samples [21]. The alpha in the
current sample for BAI was 0.87.
Procedure
In the validity study of the SHAPS in non-clinical sam-
ple, all the questionnaires were administered in groupformat to the college students. Fifty-six of them were
randomly invited to complete the SHAPS 4 weeks later.
For the clinical samples, patients with depression and
schizophrenia and healthy controls were invited to
complete the questionnaires on a one-to-one basis in
the hospital. The study was approved by the ethics com-
mittees of the Guangzhou Medical University and
informed consent was obtained from all of the
participants.Data analysis
Cronbach's α was used to assess the internal consistency
of the SHAPS. Principal component analysis, with vari-
max rotation, was performed to evaluate the factor
structure of the SHAPS. Convergent and divergent valid-
ity were assessed by evaluating the Pearson correlations
between the SHAPS total score and the scores of the
BDI, BAI, SWLS, TEPS, and PANAS. Finally, ANOVA
was performed to examine the prevalence of anhedonic
symptoms between patients with depression and schizo-
phrenia, and healthy controls, and post hoc LSD tests
were performed in cases of significant ANOVA effects.Results
Validation in non-clinical sample
The internal consistency (Cronbach's alpha) of the
SHAPS was 0.85. The mean item-total correlation was
0.50 (ranging from 0.37 to 0.59). A principal component
analysis showed a three-factor solution. The eigenvalues
of the first three factors were 4.8, 1.2, and 1.0, respect-
ively. Further inspection of the factor scores explained
34.5% of the total variance with the item load high
(mean=0.61) on the first factor.
Table 3 displays the correlations between the SHAPS
and the other measures. The SHAPS was inversely corre-
lated with the TEPS anticipatory pleasure (r=−0.47), TEPS
consummatory pleasure (r=−0.54), SWLS (r=−0.30) and
PANAS positive affect (r=−0.34), and was positively
related with the PANAS negative affect (r=0.12) and BDI
(r=0.14). In addition, no relation emerged between the
SHAPS and BAI (r=0.06). The scores of the SHAPS were
not associated with age (r=0.10). However, gender differ-
ence existed with females reporting more anhedonic
symptoms than males (t(334)=4.75, p<0.001).Test–retest reliability
The mean scores of the SHAPS on the first (20.88;
SD=4.32) and second (20.16; SD=4.36) test were not sig-
nificantly different (t(55)=1.45, p>0.05). The intraclass
correlation coefficient (ICC) between test and retest on
the SHAPS was satisfactory (r=0.64, p<0.001), suggesting
adequate test-retest reliability.
Table 3 The Pearson correlation coefficients between the SHAPS and other scales in the non-clinical sample
SHAPS TEPS_ANT TEPS_CON PANAS PA PANAS NA SWLS BDI
TEPS_ANT −0.47(**) .
TEPS_CON −0.54(**) 0.57(**)
PANAS PA −0.34(**) 0.26(**) 0.28(**)
PANAS NA 0.12(*) 0.07 −0.02 −0.10
SWLS −0.30(**) 0.16(**) 0.24(**) 0.37(**) −0.20(**)
BDI 0.14(**) −0.12(*) −0.05 −0.33(**) 0.50(**) −0.33(**)
BAI 0.06 −0.04 −0.03 −0.08 0.58(**) −0.22(**) 0.50(**)
Notes. N=336. *p<0.01, **p<0.001.
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with depression, schizophrenia and healthy controls
One-way ANOVA indicated a significant between
groups effect (F(2,282)=22.94, p<0.001) for the SHAPS
scores. Post-hoc tests showed that the patients with de-
pression (28.15±7.74) had higher SHAPS scores than the
healthy controls (21.50±5.17) and the patients with
schizophrenia (24.25±7.09) (all P<0.001). The patients
with schizophrenia had higher SHAPS scores than the
healthy controls (P<0.02).
Further analysis indicated there was an excellent in-
ternal consistency and convergence of the SHAPS in the
current clinical samples. The Cronbach's alpha of the
SHAPS for the total clinical samples (patients with de-
pression and schizophrenia) was 0.93. The mean item-
total correlation was 0.66 (ranging from 0.55 to 0.73).
The Cronbach's alphas of the SHAPS in the patients
with schizophrenia and depression were 0.91 and 0.93,
respectively. A principal factor analysis yielded a one-
factor solution for the SHAPS (eigenvalues of the first
two initial factors were 7.21 and 0.98, respectively). All
items loaded reasonably high (mean=0.72) on the
first principal factor, which explained 51.53% of the
total variance. Significant correlation was found between
the SHAPS and BDI (r=0.45, P<0.001). Moreover, the
SHAPS was inversely correlated with both the anticipa-
tory (r=−0.45, P<0.001) and consummatory pleasure
subscales (r=−0.50, P<0.001) of TEPS.
Discussion
This study examined the reliability and validity of the
SHAPS in both clinical and non-clinical samples.
The SHAPS had good internal consistency (α=0.85) and
the principal component analysis yielded a three-factor
solution in the non-clinical sample, which are in line
with the earlier findings in normal college students
population [10]. The test-retest reliability at a 4- week
interval (ICC=0.64) was similar to that reported by a
previous Dutch study (ICC=0.70) [10]. Because the
SHAPS is generally used to measure state anhedonia inneuropsychiatric patients, to some extent, the prevalence
of choosing negative items in the non-clinical population
is expected to be low and scores on the SHAPS may
change over time. Therefore, the test-retest reliability of
the SHAPS was not excellent, but at an acceptable level.
Moreover, consistent with prior studies in patients with
depression [8,10,11] and patients diagnosed with Parkin-
son’s disease [12,13], findings of this study showed that
the SHAPS had excellent internal consistency and ad-
equate construct validity, as indicated by high Cronba-
ch's alpha value (α=0.93), high item-total correlations
(mean=0.66) and a one-factor solution with the first fac-
tor accounts for 51.53% of the variance in the clinical
psychiatric samples. The findings of different dimension-
ality of the SHAPS in the non-clinical and clinical sam-
ples suggest that this scale seems to be more suitable for
assessing the hedonic capacity in clinical patients, which
is consistent with the supposition that the SHAPS was
developed as a unidimensional instrument for clinical re-
search utility [4].
Convergent and discriminant validity were assessed by
evaluating the correlations between the SHAPS total
score and other scales scores (TEPS, BDI, PANAS,
SWLS and BAI). The results demonstrated that the indi-
viduals with higher SHAPS scores displayed more defi-
cits in trait measures of anticipatory (r=−0.47) and
consummatory pleasure (r=−0.54), which indicated a
high relationship between state and trait measures of he-
donic capacity. Anhedonia measured by the SHAPS was
inversely correlated with positive affect (r=−0.34) and
mildly correlated with negative affect (r=0.12). Moreover,
the SHAPS scores had a low correlation with depression
(r=0.14) and were not related with anxiety (r=0.06). An-
hedonia is defined as the absence of pleasurable feeling,
and not the mere presence of aversive emotions (such as
negative affect, depression or anxiety). Consistent with
prior studies [7,10], these findings suggest that the valid-
ity of the SHAPS seems to be a pure measure of anhedo-
nia scale, which may tap a related but distinct construct
from depression and negative affect [7,10], and has unre-
lated psychometric properties as compared with anxiety
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with general life satisfaction (r=−0.30), suggesting that
anhedonia might decrease the feeling of life.
On the other hand, correlation analyses also showed
that the patients with depression demonstrated more an-
hedonic symptoms than the patients with schizophrenia
and non-clinical individuals. Moreover, the difference in
the SHAPS scores for the patients with schizophrenia
and healthy controls was also significant. Although an-
hedonia is an important symptom of the schizophrenia,
there is actually very little research that has examined
anhedonic symptoms measured by the SHAPS in
patients with schizophrenia. Studies suggest that patients
with schizophrenia, especially for those patients asso-
ciated with "negative" or "deficit" syndromes [25] and se-
verity of disorganization symptoms [25,26], exhibit
marked deficits in the hedonic tone when assessed using
"trait" measures of affect, but not in their state experi-
ence of pleasant stimuli [27]. Anhedonia in patients with
schizophrenia did not show consistent correlation with
depressive symptoms [28,29]. This may partly explain
that the patients with schizophrenia had lower SHAPS
scores than the patients with depression in this study.
Thus, it seems that the SHAPS scale can be used to dis-
criminate patients with depression and schizophrenia
from healthy controls.
Furthermore, this study also examined the relationship
of the SHAPS with the demographic characteristics of
the participants. We found that the SHAPS was not
associated with age and level of education, but was influ-
enced by gender. Females in Chinese sample reported
more anhedonic symptoms than males. These findings
suggest there is gender difference in the current Chinese
sample in responding to pleasant stimuli. Further studies
are needed to investigate the possible cross-cultural dif-
ferences of hedonic capacity between western and non-
western samples.
Limitations of the present study include the fact that
the sensitivity of self-report anhedonia questionnaire
has not yet been evaluated in the large clinical samples,
additional studies will also be needed to assess whether
the SHAPS scale may be useful for distinguishing
patients with different psychopathological disorders. In
addition, because inclusive scope for evaluating conver-
gent and discriminant validity of the SHAPS in this
study was relatively limited, further examination of the
relationships between the SHAPS and other scales are
required.Conclusions
To summarize, the SHAPS is an easy, simple to adminis-
ter, reliable and valid questionnaire for assessing anhedo-
nia in both patient and non-patient populations. Thesecurrent findings facilitate further research to address the
role of anhedonia in patients with depression and
schizophrenia.
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